🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration

RecruitingNAAges 27 Weeks - 34 WeeksAllHackensack Meridian Health
NCT07442669 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This prospective randomized controlled study aims to determine if using a lung ultrasound score can lead to a faster diagnosis of severe respiratory distress syndrome and quicker administration of surfactant in moderately and late-preterm infants. The research will involve 100 infants, with 67 in the prospective group and 33 serving as controls. The primary goal is to shorten the time to treatment for these vulnerable newborns. The study will also assess whether this ultrasound-guided approach improves short-term respiratory outcomes. These secondary objectives include measuring any decrease in the need for and duration of mechanical ventilation, the length of non-invasive respiratory support, and the overall need for oxygen. The study population includes infants born between 27 and 34 6/7 weeks of gestation who are admitted to the NICU. Each participant will be monitored from birth un

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Inborn at 27 0/7 to 34 6/7 weeks of gestational age * Spontaneously breathing at birth but requiring non-invasive respiratory support * RDS diagnosed on chest x-ray (diffuse, bilateral, fine granular opacities in lungs, air bronchograms) or were at risk of developing RDS Exclusion Criteria: * Outborn * Endotracheal intubation in the delivery room or within 2 hours of life * Surfactant in the delivery room as part of advanced resuscitation * Presence of major congenital malformations or chromosomal anomalies * Hydrops fetalis * Inherited disorders of metabolism * Air leak syndrome (pneumothorax, pneumomediastinum) prior to surfactant administration, congenital diaphragmatic hernia, congenital pneumonia, meconium aspiration syndrome * Infants in extremis not expected to survive
💊

What it tests

  • Lung ultrasound
📍

Where

1 site
Hackensack Univeristy Medical Center
Hackensack, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy